An Exon-Specific Small Nuclear U1 RNA (ExSpeU1) Improves Hepatic OTC Expression in a Splicing-Defective spf/ash Mouse Model of Ornithine Transcarbamylase Deficiency

Dario Balestra 1,*, Mattia Ferrarese 1, Silvia Lombardi 1, Nicole Ziliotto 1-2, Alessio Branchini 1, Naomi Petersen 3, Piter Bosma 3,4, Mirko Pinotti 1 and Stan F. J. van de Graaf 3,4

1 Department of Life Sciences and Biotechnology and LTTA, University of Ferrara, 44121 Ferrara, Italy; frrmtt1@unife.it (M.F.); lmbslv@unife.it (S.L.); zltnc1@unife.it or nicole.ziliotto@unimib.it (N.Z.); brnlss@unife.it (A.B.); pnm@unife.it (M.P.)
2 School of Medicine and Surgery, University of Milano-Bicocca, 20900 Milan, Italy
3 Tytgat Institute for Liver and Intestinal Research and Department of Gastroenterology and Hepatology, Amsterdam UMC, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands; n.petersen@amc.uva.nl (N.P.); p.j.bosma@amsterdamumc.nl (P.B.); k.f.vandegraaf@amsterdamumc.nl (S.F.J.v.d.G.)
4 Amsterdam Gastroenterology Endocrinology Metabolism, Amsterdam UMC, 1105 AZ Amsterdam, The Netherlands

* Correspondence: blsdra@unife.it; Tel.: +39-0532-974485

Received: 23 September 2020; Accepted: 17 November 2020; Published: 19 November 2020

Abstract: OTC splicing mutations are generally associated with the severest and early disease onset of ornithine transcarbamylase deficiency (OTCD), the most common urea cycle disorder. Noticeably, splicing defects can be rescued by spliceosomal U1snRNA variants, which showed their efficacy in cellular and animal models. Here, we challenged an U1snRNA variant in the OTCD mouse model (spf/ash) carrying the mutation c.386G > A (p.R129H), also reported in OTCD patients. It is known that the R129H change does not impair protein function but affects pre-mRNA splicing since it is located within the 5′ splice site. Through in vitro studies, we identified an Exon Specific U1snRNA (ExSpeU1) that targets an intronic region downstream of the defective exon 4 and rescues exon inclusion. The adeno-associated virus (AAV8)-mediated delivery of the ExSpeU1 to mouse hepatocytes, although in the presence of a modest transduction efficiency, led to increased levels of correct OTC transcripts (from 6.1 ± 1.4% to 17.2 ± 4.5%, p = 0.0033). Consistently, this resulted in increased liver expression of OTC protein, as demonstrated by Western blotting (~3 fold increase) and immunostaining. Altogether data provide the early proof-of-principle of the efficacy of ExSpeU1 in the spf/ash mouse model and encourage further studies to assess the potential of RNA therapeutics for OTCD caused by aberrant splicing.

Keywords: ornithine transcarbamylase deficiency; OTCD; splicing; U1; mice; AAV

1. Introduction

Ornithine transcarbamylase deficiency (OTCD, OMIM #311250), the most common urea cycle disorder with an estimated incidence of 1:40,000–70,000, is caused by mutations in the X-linked OTC gene encoding the mitochondrial matrix homo-trimeric enzyme that catalyzes the synthesis of citrulline, an essential step to convert the neurotoxic ammonia into urea. Therefore, OTCD is associated
with hyperammonemia leading to encephalopathy in the first days of life and, if untreated, coma and death [1]. Besides liver transplantation [2], there is no cure for OTCD but only treatments to limit hyperammonemia (low-protein diet, nitrogen scavengers, L-Arginine supplementation) and hemodialysis in extreme states [3], with a five-year survival of ~25% [4]. Several efforts have been made to develop an effective therapy, including gene therapy [5] and genome editing [6], but the objective has not been reached yet.

Among the OTC nucleotide changes reported in OTCD patients, those predicted to affect pre-mRNA splicing are generally associated with the most severe and early (neonatal) onset of the disease [7,8] and represent preferred candidates for RNA therapeutics [9]. Among these approaches, variants of the U1snRNA, the RNA components of the spliceosomal ribonucleoprotein U1RNP that drives 5′ splice site (5′ss) recognition, have been shown to rescue exon-skipping mutations in several cellular models of human disease [10–14], and also in mouse models [15,16]. Importantly, different studies demonstrated that unique U1snRNAs targeting intronic sequences downstream of a defective exon (Exon specific U1snRNA, ExSpeU1) can rescue several exon-skipping mutations at 5′ss, 3′ss or within the exon, and this was proven both in vitro and in vivo [17–21]. Very recently, we have provided the early proof of principle of efficacy in vivo of U1snRNA variants for another metabolic disorder, hereditary tyrosinemia type I [22]. In this animal model, the delivery of a compensatory U1snRNA partially rescued the causative splicing mutation at both RNA and protein levels and resulted in a slightly prolonged mice survival.

Altogether this knowledge prompted us to challenge the U1snRNA-based correction strategy in the OTCD mouse model (spf/ashl) [23,24] that carries the c.386G > A (p.R129H) mutation in the X-linked OTC gene. The predicted p.R129H amino acid substitution has no impact on mitochondrial OTC import, subunit assembly, or enzyme activity [24], whereas the corresponding c.386G > A change, occurring at the last nucleotide of OTC exon 4, and thus at the exon-intron junction, impairs OTC pre-mRNA splicing [23]. In particular, it remarkably decreases the proportion of correct transcripts and leads to the usage of a cryptic intronic 5′ss at position +49 or skipping of exon 4. Interestingly, this mutation has also been reported in OTCD patients, but in the slightly different human context, the change leads, besides exon 4 skipping, to the usage of cryptic 5′ss at position +5.

Here, by exploiting minigenes, we identified an ExSpeU1snRNA active in the mouse OTC context. Delivery of this ExSpeU1snRNA to hepatocytes, via an adeno-associated virus, partially rescued OTC splicing and protein expression in spf/ashl mice, thus providing the early in vivo proof-of-principle of the efficacy of ExSpeU1 for OTCD caused by aberrant splicing.

2. Results and Discussion

2.1. Identification of Active U1snRNA Variants by Minigene Assays

To create an experimental model useful to test correction strategies, we exploited the transient expression of mouse OTC minigenes (Figure 1A) in mouse hepatoma cells (Hepa1-6), chosen because OTC is physiologically expressed in the liver. As expected from previous minigene studies [23], the c.386G > A substitution remarkably decreased the proportion of correct transcripts and led to exon 4 skipping or the usage of a cryptic intronic 5′ss at position +49.

![Figure 1.](image-url)
Figure 1. The spf/ash ornithine transcarbamylase (OTC) mutation can be efficiently rescued by U1snRNA variants. (A) Schematic representation of the mouse OTC genomic sequence cloned as minigene in the pTB vector. Exonic and intronic sequences are represented by boxes and lines, respectively. The sequences, with exonic and intronic nucleotides in upper and lower cases, respectively, report (i) the authentic 5′ss (position +1 within intron), and (ii) the intronic cryptic 5′ss (positions +49). The nucleotide change (G > A) leading to the spf/ash phenotype is indicated. The schematic representation of engineered U1 and U7 snRNAs, with relative binding sites, is reported. Primers used for RT-PCR are indicated by arrows. (B) Evaluation of mouse OTC alternative splicing patterns in Hepa1-6 cells transiently transfected with wild-type or mutated minigenes alone or in combination with 1.5× molar excess of U1snRNA variants or the engineered U7snRNA. Amplified products were separated on 2% agarose gel (M, 100 bp molecular weight marker). Transcripts were validated by sequencing, whose electropherograms are reported below. The green arrow indicates the c.386G > A mutation.

To redirect the spliceosome to the defective 5′ss, we exploited an antisense strategy based on a modified U7snRNA, an approach successfully used by us in different gene contexts [25–27]. However, co-expression of the OTCmut minigene with a U7snRNA variant designed to target and mask the cryptic 5′ss (U7O, Figure 1A) resulted in a reduction in the cryptic 5′ss usage but increased exon 4 skipping, with a negligible impact on correct exon 4, definition. A similar effect was also reported with the use of an antisense oligonucleotide [23]. This observation indicated that U7O has been assembled into a functional snRNP, as shown by effects on cryptic 5′ss usage, but underlined an aberrant splicing mechanism due to impaired recognition of the mutated 5′ss, where the interaction with the U1snRNP is crucial. Therefore, we designed a panel of U1snRNA variants (Figure 1A) with increased complementarity with the authentic exon 4 5′ss (compensatory U1snRNA, U1O), or targeting an exonic (U1E) or downstream intronic sequences (ExSpeU1 U1O1, U1O2 U1O3). Notably, with the exception of the U1E, the co-expression of the compensatory or the exon specific U1snRNA variants with the OTCmut minigene restored exon 4 inclusion and resulted in a splicing pattern comparable to that of the OTCwt construct (Figure 1B). On the other hand, the delivery of an engineered U7snRNA designed to mask the same intronic sequence recognized by the U1O1 to U1O3 was ineffective. These data further support a mechanism in which the ExSpeU1s rescue proper exon definition by interacting with the spliceosome and not by simply interfering with a negative splicing regulatory element [19].

Altogether these data indicated that the c.386G > A mutation can be rescued by U1snRNA variants and led to the selection of the ExSpe U1O3 for studies in spf/ash mice since targeting a poorly conserved intronic sequence instead of the 5′ss sequence would most likely result in a higher gene specificity.
2.2. AAV8-Mediated Delivery of ExSpeU1\textsuperscript{O3} Partially Rescues OTC Expression

Prompted by the encouraging results in vitro, the U1\textsuperscript{O3} efficacy was challenged in the spf/ash mice by monitoring the level of OTC expression in the liver. Adult spf/ash male mice were initially kept on a low protein diet to avoid the development of a severe OTCD phenotype due to toxic ammonia levels. At 8–10 weeks, mice weighed 13 ± 2.8 g, while wild-type (wt) littermates kept on the same diet, gained weight more rapidly, and weighed 37 ± 2.9 g, confirming the growth impairment [28]. To maintain a normal rate of protein synthesis, spf/ash male mice were kept on low protein chow but supplemented with sucrose and L-Arginine, which led to a partial normalization of body weight (21 ± 5.5 g) (Figure 2A). Male mice were injected with 1 \times 10^{13} vector genomes/kg of adeno-associated virus (AAV8)-U1\textsuperscript{wt} (n = 9) or AAV8-U1\textsuperscript{O3} (n = 8) and challenged five or fourteen days later with a high protein diet (Figure 2B). Moreover, to provide evidence that the U1-mediated OTC rescue is mediated by the U1\textsuperscript{O3} binding and not by U1snRNP overexpression, the endogenous murine U1snRNA (U1\textsuperscript{wt}) was exploited as control, also because both experimental groups shared the AAV transduction effects in hepatocytes, where the OTC expression is evaluated.

The transduction efficiency, as well as the expression of the U1snRNA and the associated OTC levels in the liver, was investigated in mice at the humane endpoint, which was reached slightly later in those treated with the AAV8-U1\textsuperscript{O3} (day eight) than those with the AAV8-U1\textsuperscript{wt} (day five).

The transduction efficiency of the AAV8-U1 has been evaluated by two complementary approaches. In particular, the immune-histochemical analysis revealed that the Green Fluorescent Protein (GFP) staining, a marker of viral transduction, was comparable among mice irrespectively of the AAV8-U1 injected and not homogeneously distributed, with large variations in the number of GFP-positive hepatocytes across liver sections (Figure S1A), as previously observed by us [22,29] and others [30,31]. This finding was consistent with the AAV gene copy number that appeared to be comparable among experimental groups (Figure S1B). However, this analysis demonstrated a modest transduction efficiency (average 0.14 AAV copies/diploid genome) compared to that (>2) observed by others [32,33].

Despite the low transduction efficiency, the evaluation of correctly spliced OTC transcripts by a tailored qPCR approach revealed a significant increase in spf/ash mice injected with AAV8-U1\textsuperscript{O3} as compared to those observed in mice receiving the AAV8-U1\textsuperscript{wt} treatment (from 6.1 ± 1.4% to 17.2 ± 4.5% of those in wild-type mice, p = 0.0033) (Figure 2C, right panel). Consistently, Western blotting analysis in liver homogenates revealed a ~3-fold increase in OTC expression in spf/ash mice injected with AAV8-U1\textsuperscript{O3} compared with those injected with the AAV8-U1\textsuperscript{wt} (from 15.1 ± 2.6% to 50.1 ± 7.4% of that of the wild-type mouse used as a positive control; p = 0.0001) (Figure 2D). To further strengthen the evidence for the U1\textsuperscript{O3}-mediated rescue, we also performed OTC immunostaining in liver sections, which revealed a stronger OTC signal in AAV8-U1\textsuperscript{O3} treated mice as compared with those injected with the U1wt (Figure 2E).

As expected, the expression of the U1\textsuperscript{O3} through appropriately designed primers was clearly detectable only in spf/ash mice injected with AAV8-U1\textsuperscript{O3} (Figure 2C, left panel). Moreover, the qPCR and Western blotting confirmed that the c.386G > A (p.R129H) mutation is compatible with residual OTC expression levels, as previously reported for the spf/ash mouse model as well as in patients [23] and explaining a severe phenotype in high protein diet conditions.

Taken together, these data indicated that the AAV8-mediated delivery of the ExSpeU1\textsuperscript{O3} in spf/ash mouse liver partially rescues OTC splicing and protein levels, while the limited transduction efficiency might explain the discrepancy between the efficiency of splicing correction in vitro versus in vivo.
Figure 2. Exon Specific U1snRNA (ExSpeU1)snRNA U1 O3 restores OTC expression and ameliorates the spf/ash mouse phenotype. Asterisks represent P values: ** $p \leq 0.01$, *** $p \leq 0.001$, **** $p \leq 0.0001$ (A) Mean body weight of OTC wt and spf/ash mice kept on a low protein diet with or without the supplementation of sucrose and L-Arginine. (B) Schematic representation of the protocol designed to perform the experiments in mice and exploiting the adeno-associated virus (AAV8)-mediated delivery of the U1 O3. Five or fourteen days post-injection of $1 \times 10^{13}$ vg/kg body weight of AAV8-U1 O3, mice were challenged with a high protein diet. (C) Evaluation of U1snRNA expression (left) and correctly spliced OTC transcripts (right) in mouse liver samples. The schematic representation of the OTC gene is reported together with the exploited primers (arrows). The relative amount of correctly spliced transcripts in mice injected with the AAV8-U1 O3 as compared to those in wild-type mice (%) is reported as mean ± SD from three independent experiments. (D) Western blotting analysis in liver homogenates from spf/ash mice injected with the AAV-U1 wt or AAV-U1 O3. Each line is an individual mouse. For each experimental group, four mice were randomly selected. The mouse ATPase Na+/K+ Transporting Subunit Alpha 1 (ATP1A1) was used as load control. The virtual protein marker, reporting the molecular size of bands, is reported on the left. The bars represent the relative amount of OTC protein as compared to that of the positive control (wild-type mouse liver), quantified by densitometric analysis. Results are reported as mean ± SD from three independent experiments. (E) Immunohistochemical analysis of OTC expression in mouse liver sections. Pictures represent examples of liver sections stained with a specific anti-OTC antibody (brown). Images are taken at 20× magnification. Scale bar, 50 µm.
3. Material and Methods

3.1. Minigene Constructs and Splicing Assays

To create the pOTCwt vector, the mouse OTC exon 4 and the flanking intronic sequences (from position −546 to +615) were amplified from genomic DNA of a CL57BL6 mouse with primers 4F-4R and cloned into the expression vector pTB by using the NdeI restriction sites. The OTC c.386G > A mutation was inserted by mutagenesis (QuickChange II Site-Directed Mutagenesis Kit, Stratagene, La Jolla, CA, USA). Expression vectors for the U1snRNA and U7snRNA variants were created, as previously reported [12]. The U1 coding cassettes, either the endogenous U1 (U1wt) or the ExSpeU1 (U1O3), were cloned into an AAV8 plasmid carrying the GFP gene under the control of the PGK promoter, thus generating the AAV8-U1wt and AAV8-U1O3 plasmids.

Mouse hepatoma Hepa1-6 cells were cultured and transfected on 12-well plates [34] with 500 nanograms of each minigene construct alone or in combination with a molar excess (1.5 ×) of the pU1/pU7 plasmids. Total RNA was isolated 24 h post-transfection with Trizol (Life Technologies, Carlsbad, CA, USA), reverse-transcribed with RT-MLV (Life Technologies, Carlsbad, CA, USA) using random primers. cDNA was amplified using the plasmid-specific primers Alfa and Bra. All constructs and transcript amplicons were validated by direct sequencing. Sequences of oligonucleotides are provided in Table S1.

3.2. Procedures in Mice

The AAV8-coding plasmid was created to harbor the coding cassettes for both the U1snRNA (wild type or engineered one) and GFP genes under the control of the natural or Phosphoglycerate kinase 1 (PGK) promoters, respectively. An adenovirus-free transient transfection method [35] was exploited to generate deno-associated virus serotype 8 (AAV8), and a vector genome titer was determined, as previously described [22].

The spf/ash mouse model was obtained from Jackson Laboratories (JAX stock #001811) and subsequently bred in the Animal Research Institute of the Academic Medical Center Amsterdam. The study design and animal care and handling were approved by the Institutional Animal Care and Use Committee of the University of Amsterdam (permit A618002016775, study ALC249AB, approved 3 January 2018). Wild-type littersmates were used as control. OTC deficient animals were maintained on a low protein diet and drinking water supplemented with arginine and sucrose. OTC deficient male mice, 8-16 weeks old, received a retro-orbital injection of 1 × 10^{13} vg/kg of AAV8-U1O3 or AAV8-U1wt. Five days (4 mice injected with AAV8-U1O3 and 5 mice with AAV8-U1wt) or two weeks (4 mice/group) after injection, mice were put on a high protein diet, and the effect on body weight and overall appearance was monitored over time. A body weight loss of 20% of their maximally obtained weight was considered the humane endpoint, and mice were sacrificed. At this stage, blood samples and organs were harvested.

The study design and animal care and handling were approved by the Institutional Animal Care and Use Committee of the Academic Medical Centre of the University of Amsterdam.

3.3. Evaluation of OTC and U1O3 Expression in Mice

Total liver RNA was isolated and used to generate cDNA as described above using random primers. Levels of correctly spliced OTC transcripts were determined by quantitative PCR (qPCR) with SsoAdvanced Universal SYBER Green Supermix (Bio-Rad, Hercules, CA, USA) on diluted cDNA (1:10) with primers mOTCex3-mOTCwtex4 (Supplementary Table S1) on a CFX connect qPCR system (Bio-Rad, Hercules, CA, USA). Each sample was run in duplicate. Cq and melting curves were acquired by the use of Bio-Rad CFX Manager 3.1 software (Bio-Rad, Hercules, CA, USA). The mRNA levels were expressed as the relative expression index of 2-DDCt. Values were expressed as mean fold change standard error of the mean. OTC expression in control mice (C57BL/6) was used as a reference.

The expression of U1O3 and U1wt was evaluated on diluted cDNA (1:10) by a semi-quantitative PCR using primers U1O3Ex and U1Ex (Supplementary Table S1) followed by agarose gel electrophoresis.
OTC protein expression in mouse liver sections was detected by immunostaining of liver sections [22] using a rabbit anti-OTC polyclonal (1:200 dilution; Novus Biologicals, Centennial, CO, USA; #NBP1-87408) and a polyclonal anti-rabbit IgG-HRP as the secondary antibody (Immunologic, Duiven, The Netherlands; DPVB110 HRP) or by Western blotting (100 ug of liver homogenates) using 1:1000 dilution of the anti-OTC polyclonal antibody.

3.4. Determination of AAV Liver Transduction Levels by GFP Expression in Liver Slices and GFP Gene Copies per Liver Cell

The presence of the GFP coding gene, under the control of the PGK promoter, in the same AAV8 vector delivering the U1snRNA cassette, allowed the determination of AAV/GFP gene copies per cell by using qPCR, as previously reported [22]. Briefly, the GFP gene copy number in genomic liver DNA was determined using two GFP-specific primers (Supplementary Table S1), using a standard curve created by spiking linearized AAV8-U1\textsuperscript{wt} plasmid in mouse genomic DNA isolated from the liver of a non-treated mouse. The AAV8 vector copy number was calculated using the number of double-stranded DNA of diploid genomes normalized for the amount of genomic DNA. The lower limit of detection was 18 GFP gene copies per 10\textsuperscript{4} genomes. GFP staining was performed as previously described [22].

4. Conclusions

Through investigations in a splicing-defective mouse model of ornithine transcarbamylase deficiency, we provided the early proof-of-principle that an exon specific U1snRNA variant (U1\textsuperscript{O3}) can be exploited in vivo to rescue OTC expression impaired by a splicing defect. It is worth noting that this partial recovery was obtained in the presence of a modest transduction efficiency of hepatocytes, which may lead to an underestimation of the potential of the AAV8-U1\textsuperscript{O3} treatment. These data lay the foundation for further in vivo studies aimed at evaluating the therapeutic potential of ExSpeU1 for OTCD forms caused by aberrant splicing.

5. Patents

M.P. is the inventor of a patent (PCT/IB2011/054573) on modified U1snRNAs.

Supplementary Materials: The following are available online at http://www.mdpi.com/1422-0067/21/22/8735/s1.

Author Contributions: Conceptualization, D.B., M.P., S.F.J.v.d.G.; Methodology, M.F., S.L., N.Z., A.B., N.P.; Validation, M.F., S.L., N.Z., A.B., N.P.; Formal Analysis, N.Z.; Investigation, D.B., M.F., S.L., N.Z., A.B., N.P., P.B.; Writing—Original Draft Preparation, D.B., P.B., M.P., S.F.J.v.d.G.; Writing—Review & Editing, D.B., P.B., M.P., S.F.J.v.d.G.; Supervision, D.B., P.B., M.P., S.F.J.v.d.G.; Project Administration, D.B., M.P., S.F.J.v.d.G.; Funding Acquisition, D.B., M.P., S.F.J.v.d.G. All authors have read and agreed to the published version of the manuscript.

Funding: S.F.J.v.d.G. was supported by the Netherlands Organization for Scientific Research (VIDI 91713319) and the AMC Foundation. D.B. was supported by AFM telethon (AFM#21527). D.B., M.F., S.L., N.Z., A.B. and M.P. were also supported by the University of Ferrara.

Acknowledgments: We thank Chrystal Croes, Robert Bakker, and Suzanne Duijst for technical assistance with the mice breeding, AAV virus production, and injection.

Conflicts of Interest: D.B., M.F., S.L., N.Z., A.B., N.P., P.B. and S.F.J.v.d.G. declare no conflict of interest. M.P. is the inventor of a patent (PCT/IB2011/054573) on modified U1snRNAs. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

References

1. Wraith, J.E. Ornithine carbamoyltransferase deficiency. Arch. Dis. Child. 2001, 84, 84–88. [CrossRef] [PubMed]
2. Morioka, D.; Kasahara, M.; Takada, Y.; Shirouzu, Y.; Taira, K.; Sakamoto, S.; Uryuhara, K.; Egawa, H.; Shimada, H.; Tanaka, K. Current role of liver transplantation for the treatment of urea cycle disorders: A review of the worldwide english literature and 13 cases at Kyoto University. Liver Transpl. 2005, 11, 1332–1342. [CrossRef] [PubMed]
3. Walker, V. Ammonia toxicity and its prevention in inherited defects of the urea cycle. *Diabetes Obes. Metab.* **2009**, *11*, 823–835. [CrossRef] [PubMed]

4. Batshaw, M.L.; Tuchman, M.; Summar, M.; Seminara, J.; Summar, M.L.; Baumgartner, M.R.; Berry, S.A.; Cederbaum, S.; Diaz, G.A.; Gallagher, R.C.; et al. A longitudinal study of urea cycle disorders. *Mol. Genet. Metab.* **2014**, *113*, 127–130. [CrossRef]

5. Cunningham, S.C.; Kok, C.Y.; Spinoulas, A.; Carpenter, K.H.; Alexander, I.E. AAV-encoded OTC activity persisting to adulthood following delivery to newborn spf ash mice is insufficient to prevent shRNA-induced hyperammonaemia. *Gene Ther.* **2013**, *20*, 1184–1187. [CrossRef]

6. Yang, Y.; Wang, L.; Bell, P.; McMenamin, D.; He, Z.; White, J.; Yu, H.; Xu, C.; Morizono, H.; Musunuru, K.; et al. A dual AAV system enables the Cas9-mediated correction of a metabolic liver disease in newborn mice. *Nat. Biotechnol.* **2016**, *34*, 334–338. [CrossRef]

7. Caldovic, L.; Abdikarim, I.; Narain, S.; Tuchman, M.; Morizono, H. Genotype-phenotype correlations in ornithine transcarbamylase deficiency: A mutation update. *J. Genet. Genomics* **2015**, *42*, 181–194. [CrossRef]

8. Tuchman, M.; Jaleel, N.; Morizono, H.; Sheehy, L.; Lynch, M.G. Mutations and polymorphisms in the human ornithine transcarbamylase gene. *Hum. Mutat.* **2002**, *19*, 93–107. [CrossRef]

9. Balestra, D.; Branchini, A. Molecular mechanisms and determinants of innovative correction approaches in coagulation factor deficiencies. *Int. J. Mol. Sci.* **2019**, *20*, 3036. [CrossRef]

10. Susani, L.; Pangrazio, A.; Sobacchi, C.; Taranta, A.; Mortier, G.; Savarirayan, R.; Villa, A.; Orchard, P.; Vezzoni, P.; Albertini, A.; et al. TCIRG1-dependent recessive osteopetrosis: Mutation analysis, functional identification of the splicing defects, and in vitro rescue by U1 snRNA. *Hum. Mutat.* **2004**, *24*, 225–235. [CrossRef]

11. Tanner, G.; Glaus, E.; Barthelmes, D.; Ader, M.; Fleischhauer, J.; Pagani, F.; Berger, W.; Neidhardt, J. Therapeutic strategy to rescue mutation-induced exon skipping in rhodopsin by adaptation of U1 snRNA. *Hum. Mutat.* **2009**, *30*, 255–263. [CrossRef] [PubMed]

12. Scalet, D.; Maestri, I.; Branchini, A.; Bernardi, F.; Pinotti, M.; Balestra, D. Disease-causing variants of the conserved +2T of 5′ splice sites can be rescued by engineered U1snRNAs. *Hum. Mutat.* **2019**, *40*, 48–52. [CrossRef] [PubMed]

13. Scalet, D.; Saccheto, C.; Bernardi, F.; Pinotti, M.; Van De Graaf, S.F.J.; Balestra, D. The somatic FAH C.1061C>A change counteracts the frequent FAH c.1062+5G>A mutation and permits U1snRNA-based splicing correction. *J. Hum. Genet.* **2018**, *63*, 683–686. [CrossRef] [PubMed]

14. Balestra, D.; Giorgio, D.; Bizzotto, M.; Fazzari, M.; Ben Zeev, B.; Pinotti, M.; Landsberger, N.; Frasca, A. Splicing mutations impairing CDKL5 expression and activity can be efficiently rescued by U1snRNA-based therapy. *Int. J. Mol. Sci.* **2019**, *20*, 4130. [CrossRef] [PubMed]

15. Coutinho, M.F.; Matos, L.; Santos, J.I.; Alves, S. RNA therapeutics: How far have we gone? *Curr. Gene Ther.* **2019**, *19*, 172–196. [CrossRef] [PubMed]

16. Zhou, L.-Y.; Qin, Z.; Zhu, Y.-H.; He, Z.-Y.; Xu, T. Current RNA-based therapeutics in clinical trials. *Curr. Gene Ther.* **2019**, *19*, 1157. [CrossRef] [PubMed]

17. Dal Mas, A.; Fortugno, P.; Donadon, I.; Levati, L.; Castiglia, D.; Pagani, F. Exon-specific U1s correct SPINK5 exon 11 skipping caused by a synonymous substitution that affects a bifunctional splicing regulatory element. *Hum. Mutat.* **2015**, *36*, 504–512. [CrossRef]

18. Donadon, I.; Bussani, E.; Riccardi, F.; Licastro, D.; Romano, G.; Pianigiani, G.; Pinotti, M.; Konstantinova, P.; Evers, M.; Lin, S.; et al. Rescue of spinal muscular atrophy mouse models with AAV9-Exon-specific U1 snRNA. *Nucleic Acids Res.* **2019**, *47*, 7618–7632. [CrossRef]

19. Rogalska, M.E.; Tajnik, M.; Licastro, D.; Bussani, E.; Camparini, L.; Mattioli, C.; Pagani, F. Therapeutic activity of modified U1 core spliceosomal particles. *Nat. Commun.* **2016**, *7*, 1–13. [CrossRef]

20. Donadon, I.; McVey, J.H.; Garagliola, I.; Branchini, A.; Mortarino, M.; Peyvandi, F.; Bernardi, F.; Pinotti, M. Clustered F8 missense mutations cause hemophilia A by combined alteration of splicing and protein biosynthesis and activity. *Haematologica* **2018**, *103*, 344–350. [CrossRef]

21. Balestra, D.; Maestri, I.; Branchini, A.; Ferrarrese, M.; Bernardi, F.; Pinotti, M. An altered splicing registry EXPLAINS the Differential ExSpE1-mediated rescue of splicing mutations causing haemophilia A. *Front. Genet.* **2019**, *10*, 974. [CrossRef] [PubMed]

22. Balestra, D.; Scalet, D.; Ferrarrese, M.; Lombardi, S.; Ziliotto, N.; Croes, C.C.; Petersen, N.; Bosma, P.; Riccardi, F.; Pagani, F.; et al. A compensatory U1snRNA partially rescues FAH splicing and protein expression in a splicing-defective mouse model of tyrosinemia type I. *Int. J. Mol. Sci.* **2020**, *21*, 2136. [CrossRef] [PubMed]
23. Rivera-Barahona, A.; Sánchez-Alcuadía, R.; Viccelli, H.M.; Rüfenacht, V.; Pérez, B.; Ugarte, M.; Häberle, J.; Thöny, B.; Desviat, L.R. Functional characterization of the spf/ash splicing variation in OTC deficiency of mice and man. *PLoS ONE* 2015, 10, e0122966. [CrossRef] [PubMed]

24. Hodges, P.E.; Rosenberg, L.E. The spf(ash) mouse: A missense mutation in the ornithine transcarbamylase gene also causes aberrant mRNA splicing. *Proc. Natl. Acad. Sci. USA* 1989, 86, 4142–4146. [CrossRef] [PubMed]

25. Balestra, D.; Barbon, E.; Scalet, D.; Cavallari, N.; Perrone, D.; Zanibellato, S.; Bernardi, F.; Pinotti, M. Regulation of a strong F9 cryptic 5′ss by intrinsic elements and by combination of tailored U1snRNAs with antisense oligonucleotides. *Hum. Mol. Genet.* 2015, 24, 4809–4816. [CrossRef]

26. Scalet, D.; Balestra, D.; Rohban, S.; Bovolenta, M.; Perrone, D.; Bernardi, F.; Campaner, S.; Pinotti, M. Exploring splicing-switching molecules for seckel syndrome therapy. *Biochim. Biophys. Acta Mol. Basis Dis.* 2017, 1863, 15–20. [CrossRef]

27. Ferraresi, P.; Balestra, D.; Guittard, C.; Buthiau, D.; Pan-Petesh, B.; Maestri, I.; Farah, R.; Pinotti, M.; Giannisi-Blairot, M. Next-generation sequencing and recombinant expression characterized aberrant splicing mechanisms and provided correction strategies in factor VII deficiency. *Haematologica* 2020, 105, 829–837. [CrossRef]

28. DeMars, R.; LeVân, S.L.; Trend, B.L.; Russell, L.B. Abnormal ornithine carbamoyltransferase in mice having the sparse fur mutation. *Proc. Natl. Acad. Sci. USA* 1976, 73, 1693–1697. [CrossRef]

29. Balestra, D.; Faella, A.; Margaritis, P.; Cavallari, N.; Pagani, F.; Bernardi, F.; Arruda, V.R.; Pinotti, M. An engineered U1 small nuclear RNA rescues splicing-defective coagulation F7 gene expression in mice. *J. Thromb. Haemost.* 2014, 12, 177–185. [CrossRef]

30. Wang, L.; Wang, H.; Bell, P.; McCarter, R.J.; He, J.; Calcedo, R.; Vandenberghhe, L.H.; Morizono, H.; Batshaw, M.L.; Wilson, J.M. Systematic evaluation of AAV vectors for liver directed gene transfer in murine models. *Hum. Ther. 2010*, 18, 118–125. [CrossRef]

31. Zincarelli, C.; Soltys, S.; Rengo, G.; Rabinowitz, J.E. Analysis of AAV serotypes 1–9 mediated gene expression and tropism in mice after systemic injection. *Hum. Ther. 2008*, 16, 1073–1080. [CrossRef] [PubMed]

32. Aronson, S.J.; Bakker, R.S.; Shi, X.; Duijst, S.; ten Bloemendaal, L.; de Waart, D.R.; Verheij, J.; Ronzitti, G.; Oude Elferink, R.P.; Beuers, U.; et al. Liver-directed gene therapy results in long-term correction of progressive familial intrahepatic cholestasis type 3 in mice. *J. Hepatol.* 2019, 71, 153–162. [CrossRef] [PubMed]

33. Wang, L.; Bell, P.; Somanathan, S.; Wang, Q.; He, Z.; Yu, H.; McMenamin, D.; Goode, T.; Calcedo, R.; Wilson, J.M. Comparative study of liver gene transfer with AAV vectors based on natural and engineered AAV capsids. *Hum. Ther. 2015*, 23, 1877–1887. [CrossRef] [PubMed]

34. Ferrarese, M.; Testa, M.F.; Balestra, D.; Bernardi, F.; Pinotti, M.; Branchini, A. Secretion of wild-type factor IX upon readthrough over F9 pre-peptide nonsense mutations causing hemophilia B. *Hum. Mutat.* 2018, 39, 702–708. [CrossRef]

35. Seppen, J.; Bakker, C.; de Jong, B.; Kunne, C.; van den Oever, K.; Vandenberghhe, K.; de Waart, R.; Twisk, J.; Bosma, P. Adeno-associated virus vector serotypes mediate sustained correction of bilirubin UDP glucuronosyltransferase deficiency in rats. *Hum. Ther. 2006*, 13, 1085–1092. [CrossRef] [PubMed]

**Publisher’s Note:** MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.